Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $647,108.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar sold 92,444 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $7.00, for a total value of $647,108.00. Following the completion of the sale, the director directly owned 2,691,337 shares of the company’s stock, valued at approximately $18,839,359. This represents a 3.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Kush Parmar also recently made the following trade(s):

• On Friday, August 7th, Kush Parmar sold 52,317 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.85, for a total value of $358,371.45.
• On Thursday, August 6th, Kush Parmar sold 10,494 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.00, for a total value of $73,458.00.
• On Friday, July 31st, Kush Parmar sold 1,718 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.85, for a total value of $11,768.30.
• On Thursday, July 30th, Kush Parmar sold 114,756 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.93, for a total value of $795,259.08.

Entrada Therapeutics Price Performance

Shares of TRDA opened at $7.67 on Thursday. The stock has a market capitalization of $298.67 million, a PE ratio of -1.94 and a beta of -0.26. The business’s fifty day moving average price is $6.89 and its 200 day moving average price is $9.62. Entrada Therapeutics, Inc. has a 12-month low of $5.02 and a 12-month high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The business had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. As a group, research analysts anticipate that Entrada Therapeutics, Inc. will post -4.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Weiss Ratings cut shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. HC Wainwright downgraded Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Guggenheim reduced their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Finally, Roth Capital restated a “buy” rating and set a $11.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.75.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Ieq Capital LLC acquired a new stake in Entrada Therapeutics in the second quarter worth approximately $218,000. Great Lakes Advisors LLC acquired a new stake in shares of Entrada Therapeutics in the second quarter valued at $283,000. BlackRock Inc. acquired a new stake in shares of Entrada Therapeutics in the second quarter valued at $19,013,000. Deutsche Bank AG bought a new position in Entrada Therapeutics during the second quarter valued at about $195,000. Finally, Bank of New York Mellon Corp bought a new position in Entrada Therapeutics during the second quarter valued at about $582,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

Key Headlines Impacting Entrada Therapeutics

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $4.19 from $4.33 and its FY2027 estimate to a loss of $3.13 from $3.14. The improved longer-term forecasts may be helping sentiment, although the firm maintained a Neutral rating.
• Neutral Sentiment: HC Wainwright slightly worsened its estimates for the third and fourth quarters of 2026, forecasting losses of $1.18 and $1.04 per share, respectively. The revisions suggest continued heavy spending and ongoing losses, with the firm’s full-year FY2026 estimate still below the current consensus loss estimate of $4.07 per share.
• Neutral Sentiment: Institutional ownership remains high at approximately 86.4%. BlackRock established a new position, while Millennium Management, Citadel Advisors and Qube Research increased their holdings. These institutional purchases may provide some support, although the reported transaction periods are inconsistent and should be interpreted cautiously.
• Negative Sentiment: Major shareholder Ventures V. L.P. 5Am sold 62,811 shares for approximately $431,829 across August 6 and 7. Director Kush Parmar also sold 155,255 shares for roughly $1.08 million from August 6 through 10. The sales reduced their respective holdings but did not represent complete exits, as both continued to own substantial positions. SEC insider transaction filings
• Negative Sentiment: Entrada’s latest quarterly results were weaker than expected: the company reported a $1.01-per-share loss versus the $0.97 consensus estimate and revenue of $0.90 million versus expectations of $2.32 million. As a clinical-stage biotechnology company, TRDA remains dependent on pipeline progress and future financing rather than current operating profits.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.